Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nofazinlimab (CS1003) in Advanced Solid Tumors or Lymphomas
NCT03809767Phase 1Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nofazinlimab in solid tumor and lymphoma, sponsored by CStone Pharmaceuticals. Primary endpoints: Number of participants with adverse events and Maximum Tolerated Dose. Started Oct 2018; status: completed.
02
Drugs
nofazinlimab
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03809767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809767.